【摘要】 目的观察预混门冬胰岛素50与预混人胰岛素50R在2型糖尿病患者中的临床疗效及安全性。方法选取收治的2型糖尿病患者76例,随机分为预混门冬胰岛素50组和预混人胰岛素50R组各38例,采用2次皮下注射方案,药物剂量依据血糖调整,为期12周,观察2组患者空腹血糖、餐后2h血糖、糖化血红蛋白、低血糖事件、每日胰岛素用量。结果与预混人胰岛素50R组相比,预混门冬胰岛素50组治疗后餐后2h血糖降低明显(P<0.05),空腹血糖、糖化血红蛋白下降差异无统计学意义(P>0.05),低血糖发生率明显降低、胰岛素应用剂量减少,差异有统计学意义(P<0.05)。结论预混门冬胰岛素50在提高患者的治疗效果和依从性的同时,减少了低血糖发生,适于临床推广应用。更多还原

【Abstract】 Objective To compare the safety and efficacy of biphasic insulin aspart 50（BIAsp 50） and premixed human insulin 50（BHI 50） on type 2 diabetes mellitus（T2DM）patients.Methods A total of 76 T2 DM patients were randomly divided into BIAsp 50 group（38cases） and BHI 50 group（38 cases）.The fasting blood glucose（FBG）,2-hour postprandial blood glucose（2hPG） and glycated hemoglobin（HbA₁c） after 12 weeks’ insulin aspart 50 treatment,the insulin dosage and hypoglycemic episodes were compared.Results After 12 weeks treatment,the decrease of 2hPG in BIAsp 50 group was more than that in BHI 50 group（P<0.05）.Besides,in BIAsp 50 group,the incidence of hypoglycemic episodes was reduced,the insulin dosage was smaller,both showing significant differences（P<0.05）.ConcIusion BIAsp 50 could improve treatment efficiency and patients compliance.It is economic and suitable for widely clinical application.更多还原